Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543031 | 0.81 | HPGD (0.36) | LMNAMAPT | |
| SCHEMBL20032308 | 0.79 | TSHR (0.40) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL437917 | 0.77 | TSHR (0.50) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL13132085 | 0.77 | TSHR (0.50) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL436883 | 0.77 | TSHR (0.38) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL25868486 | 0.76 | TSHR (0.36) | TSHRKMT2AMEN1CA12CA14 | |
| SCHEMBL23802553 | 0.75 | CA12 (0.36) | TSHRKMT2AMEN1CA12CA14 | |
| SCHEMBL5839487 | 0.75 | TSHR (0.52) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL439841 | 0.75 | TSHR (0.43) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL14190511 | 0.74 | HRH3 (0.39) | TSHRKMT2AMEN1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | GIFU UNIVERSITY (JP) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | APOB, TTPA, AOX1 | TSHR 1448/4885KMT2A 3074/4885MEN1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.